China Biotechnology Services: The Group entered into a master cooperation agreement with Stella Pharma to jointly promote the development and commercialization of Steboronine® in China. This cooperation forms a synergy with the Group's flagship project at Pengbo Hainan Boron Neutron Hospital and marks an important strategic initiative of the Group to introduce advanced boron neutron therapy technology into the Chinese market to further consolidate and develop its business in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.